Sichuan Hebang Biotechnology Corporation Limited
603077.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | CN¥6,999,423 | CN¥3,064,128 | CN¥4,591,309 | CN¥1,711,028 |
| Short-Term Investments | CN¥0 | CN¥0 | CN¥0 | CN¥56,892 |
| Receivables | CN¥2,072,918 | CN¥2,049,156 | CN¥2,568,178 | CN¥1,655,936 |
| Inventory | CN¥4,544,935 | CN¥4,403,121 | CN¥2,076,049 | CN¥912,202 |
| Other Curr. Assets | CN¥180,561 | CN¥338,222 | CN¥483,336 | CN¥307,387 |
| Total Curr. Assets | CN¥14,003,269 | CN¥9,854,626 | CN¥9,718,872 | CN¥4,643,446 |
| Property Plant & Equip (Net) | CN¥9,951,912 | CN¥9,805,564 | CN¥9,482,970 | CN¥8,294,914 |
| Goodwill | CN¥1,838,406 | CN¥1,838,406 | CN¥1,838,406 | CN¥1,904,480 |
| Intangibles | CN¥2,562,149 | CN¥2,200,383 | CN¥2,170,807 | CN¥1,967,214 |
| Long-Term Investments | CN¥857,454 | CN¥667,270 | CN¥677,368 | CN¥605,103 |
| Tax Assets | CN¥127,226 | CN¥50,384 | CN¥110,299 | CN¥25,829 |
| Other NC Assets | CN¥309,318 | CN¥25,197 | CN¥103,907 | CN¥481,371 |
| Total NC Assets | CN¥15,646,465 | CN¥14,687,808 | CN¥14,383,755 | CN¥13,278,910 |
| Other Assets | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Total Assets | CN¥29,649,735 | CN¥24,542,434 | CN¥24,102,627 | CN¥17,922,356 |
| Liabilities | – | – | – | – |
| Payables | CN¥2,107,643 | CN¥1,877,499 | CN¥1,877,489 | CN¥1,156,138 |
| Short-Term Debt | CN¥2,353,237 | CN¥1,167,635 | CN¥1,221,761 | CN¥1,171,368 |
| Tax Payable | CN¥34,933 | CN¥55,012 | CN¥138,030 | CN¥223,268 |
| Deferred Revenue | CN¥0 | CN¥0 | CN¥233,784 | CN¥660,794 |
| Other Curr. Liab. | CN¥801,530 | CN¥451,454 | CN¥425,792 | CN¥425,380 |
| Total Curr. Liab. | CN¥5,374,509 | CN¥3,669,942 | CN¥3,734,335 | CN¥3,123,148 |
| LT Debt | CN¥4,935,444 | CN¥430,665 | CN¥408,000 | CN¥68,093 |
| Deferred Rev, NC | CN¥130,166 | CN¥0 | CN¥79,030 | CN¥16,786 |
| Deferred Tax Liab, NC | CN¥187,923 | CN¥122,752 | CN¥96,022 | CN¥39,990 |
| Other NC Liab. | CN¥650 | CN¥75,749 | CN¥477 | CN¥0 |
| Total NC Liab. | CN¥5,268,708 | CN¥654,110 | CN¥605,074 | CN¥161,928 |
| Other Liabilities | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Cap. Leases | CN¥14,525 | CN¥24,944 | CN¥21,545 | CN¥37,060 |
| Total Liabilities | CN¥10,643,216 | CN¥4,324,052 | CN¥4,339,409 | CN¥3,285,076 |
| Equity | – | – | – | – |
| Pref Stock | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Common Stock | CN¥8,831,250 | CN¥8,831,250 | CN¥8,831,250 | CN¥8,831,250 |
| Retained Earnings | CN¥9,477,660 | CN¥9,504,633 | CN¥8,824,794 | CN¥5,292,684 |
| AOCI | CN¥1,138,549 | CN¥66,405 | CN¥1,281,623 | CN¥608,117 |
| Other Equity | CN¥0 | CN¥847,375 | CN¥1,252,168 | CN¥4,836 |
| Total Equity | CN¥18,626,392 | CN¥19,575,342 | CN¥19,118,357 | CN¥14,245,437 |
| Supplemental Information | – | – | – | – |
| Minority Interest | CN¥380,126 | CN¥643,040 | CN¥644,862 | CN¥391,843 |
| Total Liab. & Tot. Equity | CN¥29,649,735 | CN¥24,542,434 | CN¥24,102,627 | CN¥17,922,356 |
| Net Debt | CN¥289,258 | -CN¥1,465,828 | -CN¥2,961,548 | -CN¥471,567 |